Editorial Open Access
Copyright ©2008 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Feb 7, 2008; 14(5): 657-665
Published online Feb 7, 2008. doi: 10.3748/wjg.14.657
Occult sporadic insulinoma: Localization and surgical strategy
Bassam Abboud, Department of General Surgery, Hotel Dieu de France Hospital, Faculty of Medicine, Saint-Joseph University, Beirut 166830, Lebanon
Joe Boujaoude, Department of Gastroenterology, Hotel Dieu de France Hospital, Faculty of Medicine, Saint-Joseph University, Beirut 166830, Lebanon
Author contributions: Abboud B and Boujaoude J designed research; Abboud B and Boujaoude J performed research, Abboud B wrote the paper
Correspondence to: Bassam Abboud, MD, Department of General Surgery, Hotel Dieu de France Hospital, Alfred Naccache Street, Beirut 166830, Lebanon. dbabboud@yahoo.fr
Telephone: +961-1-615300
Fax: +961-1-615295
Received: November 21, 2007
Revised: December 3, 2007
Published online: February 7, 2008

Abstract

Insulinomas continue to pose a diagnostic challenge to physicians, surgeons and radiologists alike. Most are intrapancreatic, benign and solitary. Biochemical diagnosis is obtained and imaging techniques to localize lesions continue to evolve. Surgical resection is the treatment of choice. Despite all efforts, an occult insulinoma (occult insulinoma refers to a biochemically proven tumor with indeterminate anatomical site before operation) may still be encountered. New localization preoperative techniques decreases occult cases and the knowledge of the site of the mass before surgery allows to determine whether enucleation of the tumor or pancreatic resection is likely to be required and whether the tumor is amenable to removal via a laparoscopic approach. In absence of preoperative localization and intraoperative detection of an insulinoma, blind pancreatic resection is not recommended.

Key Words: Insulinoma; Occult; CT scan; Endoscopic ultrasonography; Surgery; Laparoscopy



INTRODUCTION

Although rare, insulinomas are the most common functioning islet cell tumor of the pancreas. Recognition of the key neuroglycopenic symptoms should trigger the initial investigation. Biochemical proof of endogenous hyperinsulinemic hypoglycemia establishes the diagnosis. Several options are available for imaging and localizing these tumors. The tumors are usually small, single, benign, well-circumscribed, and evenly distributed throughout the pancreas. This tumor may be a part of the multiple endocrine neoplasia type 1 (MEN-1) syndrome. Surgical treatment is the only curative method. Patients are almost invariably cured lifelong with complete excision of a benign insulinoma[110]. Medical therapy can control hypoglycemic symptoms in approximately 50%-60% of patients with insulinoma, but operation remains the only curative treatment. The urgency of surgery is related to the severity of symptoms and the ability to manage them medically. In general, if hypoglycemia can be managed medically, there is less immediate pressure on the surgeon to find and remove the tumor. However, if symptoms are poorly controlled with medical management, the operation must be successful[5].

Most of the time it is easy to diagnose, localize and remove insulinoma, allowing complete alleviation of the dramatic, and sometimes life-threatening, symptoms of neuroglycopenia. Sometimes, however, this may not be so; despite adequate knowledge of its size and location, an insulinoma may be “occult” (occult insulinoma refers to a biochemically proven tumor with indeterminate anatomical site before operation) and difficult to localize[1114]. What is (are) the technique(s) of choice to localize insulinoma? What surgical approach will be adopted in case of occult insulinoma? To respond to this important issue, we must discuss the different localization studies with operative procedure options.

EPIDEMIOLOGY OF INSULINOMA

Insulinoma are rare and small neuroendocrine tumors with an incidence of approximately one to four per million per year. It is the most common pancreatic islet cell tumor (25% of endocrine pancreatic tumors) and is malignant in only 5%-11% of cases. Virtually all insulinomas are intrapancreatic in location[135]. Extrapancreatic insulinomas with symptoms of hypoglycaemia are extremely rare (2%) and are most commonly found in the duodenal wall. In its sporadic form (90%) tumors are generally solitary, whereas in its familial form (5%-10%), they are multiple, especially in the setting of the multiple endocrine neoplasia (MEN) type 1 syndrome. Approximately 80%-90% of insulinomas are less than 2 cm in size and the lesions are distributed equally throughout the head, body and tail of the pancreas. Most insulinomas are benign (90% of cases). Two per cent of patients have diffuse islet cell hyperplasia, microadenomatosis, or adult nesidiblastosis. Although insulinoma may occur throughout life, the mean age at presentation is 45 (range 8-82) years, and there is a female preponderance (female to male ratio 1.4:1). In MEN 1 the mean age at presentation is younger, at 25 years or less[15].

CLINICAL PRESENTATION

Almost all patients with an insulinoma present with symptoms of hypoglycemia secondary to excessive and uncontrolled secretion of insulin[11]. In the case of an insulinoma, symptoms are typically evident in the morning after an overnight fast, and are often precipitated by exercise[15]. Patients learned to avoid symptoms by eating frequent small meals and sugary snacks, with resultant weight gain. Symptoms are often misinterpreted, non-specific, episodic, vary among individuals and can differ from time to time in the same individual. So it is important to obtain a plasma glucose level during symptoms because a normal value in this case rules out the possibility of an insulinoma[5]. Hypoglycemic symptoms can be divided into two categories: neuroglycopenic and neurogenic symptoms[1617]. Neuroglycopenic symptoms are due to central nervous system neuronal glucose deprivation. They include behavioral changes, confusion, lethargy, weakness, transient motor deficits, difficulty awakening, visual changes, fatigue, seizures and loss of consciousness[1820]. If hypoglycemia is severe and prolonged, death may result. Neurogenic symptoms are are due to autonomic nervous system discharge caused by hypoglycemia. This results in cholinergic symptoms including hunger, sweating and parasthesia, and adrenergic symptoms including anxiety, tremor and palpitations. Erroneous psychiatric or neurological diagnoses are common in such situations and, on average, it takes up to 2 years before the correct diagnosis is made[5].

CLINICAL EVALUATION

In general, venous plasma glucose levels higher than 3.9 mmol/L after an overnight fast are normal; levels between 2.8 mmol/L and 3.9 mmol/L suggest hypoglycemia and lower than 2.8 mmol/L indicates hypoglycemia. Accurate diagnosis relies upon demonstration of symptomatic hypoglycemia with objective biochemical evidence of cell hypersecretion in the absence of factitious use of an insulin secretagogue. Whipple originally proposed the diagnostic triad of symptomatic hypo-glcemia induced by fasting, a blood glucose level below 2.48 mmol/L (0.45 g/L), and prompt relief of symptoms following administration of glucose[5]. A corresponding rise in C-peptide is crucial to verify that insulin secretion is endogenous and to exclude factitia, i.e. self administration of insulin or peroral antidiabetic medication, claimed to be more common than insulinoma. Undetectable C-peptide in a hypoglycemic patient with an elevated insulin level would indicate exogenous insulin administration. Proinsulin levels in normal individuals are usually < 20% of total immunoreactive insulin but tend to be higher in patients with insulinoma. Proinsulin/insulin ratio > 50% may indicate malignant insulinoma, but occurs also with 25% of benign insulinomas. Oral sulphonylurea antidiabetics may cause hypoglycaemia with rise in insulin, C-peptide and proinsulin, and should be excluded by plasma measurement. The use of a ratio of insulin to glucose to aid in the diagnosis has been advocated by some authors but have evidence that they may be misleading. In one series, 34% of patients with excised insulinomas had insulin to glucose ratio > 0.30, demonstrating the fallibility of this ratio. The absolute values of glucose and insulin are the keys: when the glucose level drops to 0.45 g/L, any measurable insulin is abnormal[52123]. A supervised 72 h fast forms the basis for the diagnosis of endogenous hyperinsulinemia[2425]. The critical pathophysiological feature is failure of insulin secretion to fall to very low rates during episodes of hypoglycemia. From published reports, symptoms develop in 35% of patients within 12 h, 75% within 24 h, 92% within 48 h and 99% within 72 h[22]. The presence of hypoglycemic symptoms with fulfillment of the following criteria is diagnostic of insulinoma: blood glucose level 2.5 mmol/L or lower, insulin level 6 units/mL or higher, C-peptide level 0.2 nmol/L or higher, plasma proinsulin level 0.5 nmol/L or higher, plasma beta-hydroxybutyrate 2.7 mmol/L or lower, change in blood glucose of 0.25 g/L or higher at 30 min after 1 mg intravenous glucagon, and a negative sulphonylurea screen in the plasma and/or urine[21].

DIFFERENTIAL DIAGNOSIS

Hypoglycemia due to excessive endogenous insulin secretion can be caused by a primary pancreatic beta cell disorder including an insulinoma, beta cell hyperplasia or nesidioblastosis (presence of diffuse microadenomatosis, in which multiple small non-encapsulated tumors or nodules are distributed throughout the pancreas), a beta cell secretagogue including a sulphonylurea or a beta cell-stimulating antibody, or an antibody to insulin[202629]. The differential diagnosis of hypoglycaemia includes hormonal deficiencies, hepatic insufficiency, exogenous hyperinsulinism, medication, drugs and enzyme defects. Occasionally differentiating insulinoma from these other causes of hypoglycaemia can be quite difficult. Hypoglycemia was reported in the setting of some tumors and of advanced gastrointestinal stromal tumors. Patients with multiple myeloma or systemic lupus erythematosus (SLE) and hypoglycaemia may have anti-insulin antibodies. These antibodies bind and release insulin in an unregulated manner, resulting in hypoglycaemia. These patients can be distinguished from patients with insulinoma by an anti-insulin antibody test[203032].

LOCALIZATION STUDIES

The localization of small functioning islet cell tumors has proved a challenge to endocrinologists, surgeons and radiologists for several decades. No single imaging test has emerged as being clearly superior. Imaging to localize insulinomas should only take place once the diagnosis has been confirmed biochemically. The role of imaging is not to diagnose insulinomas, but to identify and localize the tumor. Because virtually all insulinomas are found in the pancreas, it should be the focus of attention; no ectopic insulinomas have been encountered throughout the Mayo Clinic experience[3]. A number of techniques are available to localize an insulinoma, including transabdominal ultrasonography, abdominal computed tomography (CT), magnetic resonance imaging (MRI), arteriography, endoscopic ultrasonography (EUS), transhepatic portal venous sampling, selective arterial calcium stimulation with heptic venous sampling, 111 In-labelled octreotide scan with single photon emission tomography, intraoperative ultrasonography and intraoperative palpation.

Conventional preoperative techniques

Conventional imaging studies such as ultrasonography, computed tomography, and magnetic resonance imaging fail to reveal the majority of insulinomas[53336]. The reported sensitivity of conventional CT scan, MRI, and ultrasonography for detection of pancreatic insulinoma ranges from about 30% to 66%, 37% to 71%, and 9.6% to 61% respectively. Combined Conventional CT scan, MRI and ultrasonography identify 17% to 66% of insulinoma[53639]. With these conventional preoperative techniques, occult insulinoma was present in 31% to 52% of cases in some series[1213]. The incidence of patients with occult insulinomas seen at the national institutes of health, increased from 16% to 52%[13].

Arteriography was considered the ‘gold standard’ for insulinoma localization. However, reported sensitivities of 29%-64%, combined with improved non invasive imaging modalities, have decreased its use[33354041].

Intraoperative techniques

Because of the inability of conventional preoperative studies to localize an insulinoma accurately, some have recommended surgical exploration with intraoperative ultrasonography (IOUS), thereby avoiding other costly preoperative imaging techniques. The most effective method for localizing an insulinoma at surgery is intraoperative ultrasonography[4248]. Combining many of the attributes of preoperative ultrasonography but also enhanced by the ability to image the pancreas directly without the interference of overlying organs or gas, IOUS has been highly useful in localizing these small tumors. However, it is labour intensive, extremely operator dependent, and, without any definite preoperative localization, obviously focuses the immediate pressure to localize the tumor on the shoulders of the radiologist and ultimately the surgeon. Relevant operative anatomy can be examined to determine the optimal resection method with respect to proximity of the tumor to the main pancreatic duct, combined with colour flow Doppler assessment of adjacent major vessels. It can guide the safest approach to a tumor and facilitate dissection from the pancreatic duct, and also reveal tumor bilobation that has to be appreciated at enucleation. Sensitivities of up to 95% are reported in the detection of pancreatic insulinomas especially useful for tumors in the thicker pancreatic head. Islet cell tumors appear as well-defined, hypoechoic lesions on ultrasonography. The insulinoma is seen as a sonolucent and discrete mass. IOUS is now considered a necessary prerequisite for insulinoma operation together with complete pancreatic exploration and palpation at surgery. The IOUS should be done by an experienced investigator, and can identify tumors larger than 2-3 mm.

Most insulinomas are intraoperatively palpable as a firmer nodule with sensitivity of 90%. Tumors deep within the pancreatic head and in the uncinate process are difficult to palpate, and any lesion is difficult to detect in patients with previous pancreatitis. Combination of IOUS and palpation increases the sensitivity of insulinoma detection to nearly 100%, but requires complete surgical exploration. The head of the pancreas is delivered by the Kocher manoeuvre, with the uncinate process carefully dissected towards the porto-mesenteric vein. The pancreatic tail is mobilized to the mesenteric vein, allowing bidigital palpation and IOUS investigation from both dorsal and ventral surfaces[434548].

Intraoperative laparoscopic ultrasonography greatly facilitates tumor localization and is valuable in guiding the site of pancreatic transection or enucleation especially with respect to the pancreatic ducts. It also defines the relationship of the tumor to the mesenteric vessels and confirms the adequacy of resection. Additionally, it readily demonstrates the relevant operative anatomy, defining the relationship of the tumor to the pancreatic and bile duct, and adjacent blood vessels[4952].

New preoperative techniques

Transabdominal ultrasonography with frequency probes of 7.5-12 MHz allows higher image resolution. The advent of helical CT scanning has improved the detection of insulinomas compared with conventional CT[55356]. Much investigation has gone into determining the optimal phase for detection and the consensus shows that the use of CT in the early phases is the most sensitive. Diagnostic sensitivity was 94% for dual-phase thin-section multidetector CT, 56% for dual-phase multidetector CT without thin sections and 29% for sequential CT. MR imaging is usually reserved for the detection of small and non-organ-deforming pancreatic tumors, including the functional islet-cell tumors. In current practice MRI is a second-line investigation, but potentially could take over from CT in the future as it becomes more widely available and expertise improves. For some authors, magnetic resonance imaging enables localization of small pancreatic insulinomas[5762]. For others, while tumor detection increases with tumor size, MRI has been shown to be more accurate than CT, especially for the detection of smaller tumors. Multiple lesions are more difficult to detect using either modality. Current studies still emphasize that MRI is more sensitive for tumor detection. Nevertheless, in many institutions worldwide, CT remains the main imaging method for assessment of pancreatic disease, due largely to its wide availability.

EUS appears to be emerging as one of the best preoperative studies to identify insulinoma. However, it requires considerable specialized expertise, is observer dependant and is not available in all centers. Sensitivities of up to 94% (range 57%-94%) are reported[6365]. It has a specificity of 95% for identifying intrapancreatic insulinomas. The combination of biphasic thin-section helical CT and EUS resulted in an overall diagnostic sensitivity of 100%[66]. The EUS appearances of insulinoma are characteristic and include homogenous hypoechoic, rounded lesions with distinct margins. The availability of linear and curvilinear array EUS has broadened its applicability, with the ability to perform fine-needle aspiration cytology of suspicious lesions, contrast-enhanced EUS using Levovist and preoperative marking of lesions to facilitate surgical excision[6772]. EUS can reveal important relation to the pancreatic duct, and if introduced in the horizontal duodenum allows visualization also of the uncinate process; some of the equipment may be used for tumor biopsy. It has appeared as the most efficient method for preoperative localization, although some isoechoic (6%) or pedunculated tumors may fail to be visualized. Other limitations of EUS include poor evaluation of lesions in the distal body or pancreatic tail[7374]. Detection rates of 83%-100% of head and body lesions are reported compared with 37%-60% for pancreatic tails lesions[5]. Intraduct ultrasonography has been used to identify small islet cell tumors, and shows promise in differentiating benign from malignant causes of localized stenosis of the main pancreatic duct. It has a reported detection rate of over 90% in the diagnosis of 1-3-mm diameter lesions. However, it is not widely available, requires specialist skills to perform and interpret, and will probably remain confined to selected centres[7576].

Transhepatic portal venous sampling and selective arterial calcium stimulation with hepatic venous sampling have been proposed as the most sensitive preoperative localization techniques by some authors[7784]. Selective arterial calcium stimulation with hepatic venous sampling is a more sensitive and specific provocative test, and has largely replaced transhepatic portal venous sampling. This technique has a reported sensitivity of over 90% (range 87.5%-100%) in the accurate localization of pancreatic insulinomas. Although selective arterial calcium stimulation with hepatic venous sampling has a high detection rate, it is not used routinely in most centers as it is invasive, technically demanding and expensive. It may be appropriate when an insulinoma is strongly suspected but all non-invasive imaging tests are negative.

Insulinomas have a low density of somatostatin receptor in only 50% of tumors[85]. Consequently, somatostatin receptor scintigraphy has a limited role in the evaluation of primary insulinomas. Evolving techniques include peptide receptor scintigraphy combined with anatomic imaging methods such as CT or positron emission tomography[5765]. In tumors that express somatostatin receptor, this can be determined along with detailed axial imaging. This technique has a role in tumor localization, and also for follow-up after treatment with peptide receptor radionuclide therapy[8693].

PREOPERATIVE LOCALIZATION IS NECESSARY?

Avoiding all efforts at preoperative localization has been espoused by some because a relatively high percentage of insulinomas can be identified intraoperatively in the hands of experienced surgeons. However, reports of insulinomas that remain undetected range from 10% to 27% in several series and preoperative localization was considered essential to successful surgical treatment’ in 15 of 41 (37%) patients at one major medical centre with a highly experienced endocrine surgeon. There is absolutely no question that positive localization is required prior to reoperative insulinomas. Preoperative localization is very helpful in planning the operation and certainly offers a measure of comfort to both the surgeon and patient prior to entering the operating room. However, preoperative imaging enables more accurate surgery, which may spare the patient an unnecessary total pancreatectomy and its associated morbidities, and facilitates the detection of metastases. Furthermore, it avoids prolonging the duration of surgery and potential intraoperative damage to major structures such as the splenic vein. It is agreed by the majority, however, that knowledge of the site of the tumor before surgery is helpful in that it allows one to determine not only whether enucleation of the neoplasm or pancreatic resection is likely to be required but also whether the tumor is amenable to removal via a laparoscopic approach. It should also mean that the operation itself can be performed more rapidly, thereby reducing its reported morbidity and mortality. Many surgeons emphasize the importance of preoperative localization of insulinomas, because 10%-20% of these lesions cannot be identified during surgical exploration. With recent advances in non-invasive imaging giving a detection rate fast approaching that of intra-operative imaging, the present consensus is generally that preoperative localization is worthwhile. The combination of biphasic thin-section helical CT and EUS resulted in an overall diagnostic sensitivity of 100%[66] and constituted the preoperative localization study of choice.

OPERATIVE MANAGEMENT

Surgical resection is the treatment of choice and offers the only chance of cure. Overall cure rates of 75%-98% are reported after surgery, with prognosis dependant on the stage at presentation and whether complete resection was achieved[9498]. The surgery may use laparoscopic or open techniques, and includes enucleation, and/or resection. With advances in laparoscopic techniques, both laparoscopic enucleation and resection of pancreatic insulinoma have been performed successfully in many centers, and can be associated with markedly reduced hospital stay and increased patient comfort[99124]. The operation is facilitated by laparoscopic ultrasonography, but may be complicated-especially in the case of pancreatic head tumors-by higher risk of pancreatic effusion (20%-40%). This operation can be chosen for carefully selected lesions and should be performed by expert laparoscopists. Enucleation is indicated for small, benign tumors at least 2-3 mm from the main pancreatic duct. Intraoperative ultrasonography can be used to measure the distance between the tumor margin and the main pancreatic duct. Macroscopically, lesions appear reddish-brown in colour in contrast to the surrounding yellowish pancreatic parenchyma, and possess a pseudocapsule with a clear plane of dissection between the tumor and the surrounding soft pancreatic parenchyma. Recent guidelines suggest enucleation is enough if the lesion is clearly localized before surgery, near or at the pancreatic surface, and easily defined intraoperatively. Histologic confirmation of complete excision and the benign nature of the insulinoma are essential[66]. Resection is indicated when the tumor abuts the pancreatic duct or major vessels, or where malignancy is suspected with a hard, infiltrating tumor and puckering of the surrounding soft tissue, distal dilatation of the pancreatic duct or lymph node involvement[102]. Resection options include distal pancreatectomy (with or without splenectomy), pylorous-preserving Whipple procedure, or mid-body pancreatectomy, depending on the site of insulinoma. To determine completeness of tumor excision, a perioperative insulin assay is valuable[125127]. Intraoperative frozen section can provide information regarding the nature of the tissue, but is often non-diagnostic and cannot assess features of malignancy accurately. Completeness of excision is assessed by gross pathological appearance and should be confirmed by formal histological examination[102]. In 80% of patients with MEN 1 who have endogenous hyperinsulinemia, there are multiple pancreatic tumors. In these patients, an 80%-85% subtotal pancreatectomy to the level of the portal vein with enucleation of lesions in the head of the gland is recommended to reduce the risk of exocrine and endocrine insufficiency. After successful surgical excision, overall 5-year survival has been 97% (5.96); the long-term survival is 88% at 10 years with a higher risk of recurrence in patients with MEN 1[5]. After resection, the risk of recurrence is greater in patients with MEN 1 (21% at 20 years) than those without MEN 1 (5% at 10 years and 7% at 20 years).

OCCULT INSULINOMA

Insulinomas continue to pose a diagnostic challenge to physicians, surgeons and radiologists alike. With the new preoperative localization techniques, especially the combination of biphasic thin-section helical CT and EUS resulted in an overall diagnostic sensitivity of 100%, very few cases of occult insulinoma may still be encountered. In the past, different strategies have been used to deal with this problem. Blind distal pancreatectomy, progressive pancreatectomy and subtotal pancreatectomy with intraoperative glucose monitoring have hitherto been recommended. Blind distal and progressive pancreatectomy are no longer indicated if no insulinoma is found, since recent studies indicate that occult tumors are more commonly located within the pancreatic head[134243100]. As insulinomas are small and the pancreatic head parenchyma is thick, most non-palpable tumors are in the pancreatic head. Intraoperative ultrasonography can play a critical role in the identification of non-palpable lesions. In a series by Norton[43], only 33% of insulinomas in the pancreatic head were palpable. However, intraoperative ultrasonography correctly identified 100% of them. Still, it is difficult to advocate performing a Whipple procedure on the basis of circumstantial evidence that the tumor may be present in the pancreatic head. If the tumor is not identified despite a careful exploration with intraoperative ultrasonography, termination of the operation without blind resection is recommended. In such cases the surgical procedure should be terminated, the abdomen should be closed, the patient referred to a specialist centre[134244], and subjected to further investigation to verify the biochemical diagnosis and exclude factitious insulin administration. A repeat 72 h fast may be necessary to be certain of the diagnosis. A trial of the best current medical therapy to stabilize the patient on a short-term basis allows time for more extensive localization procedures applied before reoperation, often including the SAS intra-arterial calcium injection test[13100], a technique that is useful in localizing the region of the pancreas containing the tumor. At re-exploration, if still no tumor is identified, the area of the pancreas suggested by the calcium angiogram should be removed. One might call this an enlightened resection rather than a blind resection.

MEDICAL MANAGEMENT

Medical management of insulinoma is generally restricted to high-risk candidates for surgery, those not suitable for resection or in those who have undergone an unsuccessful operation with persistent symptoms. Options include dietary management, diazoxide, calcium channel blockers and somatostatin analogues. Patients are advised to avoid prolonged fasting and to take frequent meals and snacks, including complex carbohydrates. The recommended daily dose of diazoxide is 200-600 mg orally. Good symptom control is achieved in about 50% of patients. However significant side effects of edema, weight gain, hirsutism and nausea are common. The calcium channel blocker, verapamil, has also been used with some success[102]. Octreotide, a synthetic somatostatin analogue results in only temporary and modest symptom relief. It can worsen hypoglycemic symptoms owing to a grater suppressive effect on growth hormone and glucagon secretion than on insulin. A satisfactory response is reported in only 50% of patients[5128129].

CONCLUSION

Insulinomas are uncommon tumors. Most are intra-pancreatic, benign and solitary. A biochemical diagnosis obtained during a supervised 72 h fast followed by high quality dual phase thin section multidetector CT of the pancreas and endoscopic ultrasound confirms the diagnosis and localize the insulinoma in the majority of patients and few cases of occult insulioma may persist. Intraoperative palpation and ultrasonography should enable accurate tumor localization if preoperative studies fail to localize insulinoma. If the tumor still occult, blind pancreatic resection is not recommended. Laparoscopic treatment is increasingly performed, and leads to long term cure if the tumor is benign.

Footnotes

Peer reviewer: Ian C Roberts-Thomson, Professor, Department of Gastroenterology and Hepatology, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville South 5011, Australia

References
1.  Jani N, Moser AJ, Khalid A. Pancreatic endocrine tumors. Gastroenterol Clin North Am. 2007;36:431-439, x-xi.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Stephen AE, Hodin RA. Neuroendocrine tumors of the pancreas, excluding gastrinoma. Surg Oncol Clin N Am. 2006;15:497-510.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19:783-798.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753-781.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Tucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg. 2006;93:264-275.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Jyotsna VP, Rangel N, Pal S, Seith A, Sahni P, Ammini AC. Insulinoma: Diagnosis and surgical treatment. Retrospective analysis of 31 cases. Indian J Gastroenterol. 2006;25:244-247.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Proye CA, Lokey JS. Current concepts in functioning endocrine tumors of the pancreas. World J Surg. 2004;28:1231-1238.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66:711-719.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Delcore R, Friesen SR. Gastrointestinal neuroendocrine tumors. J Am Coll Surg. 1994;178:187-211.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Van Nieuwenhove Y, Vandaele S, Op de Beeck B, Delvaux G. Neuroendocrine tumors of the pancreas. Surg Endosc. 2003;17:1658-1662.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Dolan JP, Norton JA. Occult insulinoma. Br J Surg. 2000;87:385-387.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  van Heerden JA, Grant CS, Czako PF, Service FJ, Charboneau JW. Occult functioning insulinomas: which localizing studies are indicated? Surgery. 1992;112:1010-1014; discussion 1014-1015.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Norton JA, Shawker TH, Doppman JL, Miller DL, Fraker DL, Cromack DT, Gorden P, Jensen RT. Localization and surgical treatment of occult insulinomas. Ann Surg. 1990;212:615-620.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Stringel G, Dalpe-Scott M, Perelman AH, Heick HM. The occult insulinoma operative localization by quick insulin radioimmunoassay. J Pediatr Surg. 1985;20:734-736.  [PubMed]  [DOI]  [Cited in This Article: ]
15.  Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Insulinoma with early-morning abnormal behavior. Intern Med. 2007;46:405-408.  [PubMed]  [DOI]  [Cited in This Article: ]
16.  Cryer PE. Symptoms of hypoglycemia, thresholds for their occurrence, and hypoglycemia unawareness. Endocrinol Metab Clin North Am. 1999;28:495-500, v-vi.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  DeRosa MA, Cryer PE. Hypoglycemia and the sympatho-adrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab. 2004;287:E32-E41.  [PubMed]  [DOI]  [Cited in This Article: ]
18.  Jaladyan V, Darbinyan V. Insulinoma misdiagnosed as juvenile myoclonic epilepsy. Eur J Pediatr. 2007;166:485-487.  [PubMed]  [DOI]  [Cited in This Article: ]
19.  Graves TD, Gandhi S, Smith SJ, Sisodiya SM, Conway GS. Misdiagnosis of seizures: insulinoma presenting as adult-onset seizure disorder. J Neurol Neurosurg Psychiatry. 2004;75:1091-1092.  [PubMed]  [DOI]  [Cited in This Article: ]
20.  Marks V, Teale JD. Hypoglycemic disorders. Clin Lab Med. 2001;21:79-97.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:33-41.  [PubMed]  [DOI]  [Cited in This Article: ]
22.  Vezzosi D, Bennet A, Fauvel J, Caron P. Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol. 2007;157:75-83.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Piovesan A, Pia A, Visconti G, Terzolo M, Leone A, Magro G, Cesario F, Borretta G. Proinsulin-secreting neuroendocrine tumor of the pancreas. J Endocrinol Invest. 2003;26:758-761.  [PubMed]  [DOI]  [Cited in This Article: ]
24.  Service FJ, Natt N. The prolonged fast. J Clin Endocrinol Metab. 2000;85:3973-3974.  [PubMed]  [DOI]  [Cited in This Article: ]
25.  Hirshberg B, Livi A, Bartlett DL, Libutti SK, Alexander HR, Doppman JL, Skarulis MC, Gorden P. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab. 2000;85:3222-3226.  [PubMed]  [DOI]  [Cited in This Article: ]
26.  Marks V, Teale JD. Hypoglycemia: factitious and felonious. Endocrinol Metab Clin North Am. 1999;28:579-601.  [PubMed]  [DOI]  [Cited in This Article: ]
27.  Raffel A, Anlauf M, Hosch SB, Krausch M, Henopp T, Bauersfeld J, Klofat R, Bach D, Eisenberger CF, Kloppel G. Hyperinsulinemic hypoglycemia due to adult nesidioblastosis in insulin-dependent diabetes. World J Gastroenterol. 2006;12:7221-7224.  [PubMed]  [DOI]  [Cited in This Article: ]
28.  Kaczirek K, Soleiman A, Schindl M, Passler C, Scheuba C, Prager G, Kaserer K, Niederle B. Nesidioblastosis in adults: a challenging cause of organic hyperinsulinism. Eur J Clin Invest. 2003;33:488-492.  [PubMed]  [DOI]  [Cited in This Article: ]
29.  Raffel A, Krausch M M, Anlauf M, Wieben D, Braunstein S, Kloppel G, Roher HD, Knoefel WT. Diffuse nesidioblastosis as a cause of hyperinsulinemic hypoglycemia in adults: a diagnostic and therapeutic challenge. Surgery. 2007;141:179-184; discussion 185-186.  [PubMed]  [DOI]  [Cited in This Article: ]
30.  Marks V, Teale JD. Tumours producing hypoglycaemia. Diabetes Metab Rev. 1991;7:79-91.  [PubMed]  [DOI]  [Cited in This Article: ]
31.  Guiteau J, Fanucchi M, Folpe A, Staley CA 3rd, Kooby DA. Hypoglycemia in the setting of advanced gastrointestinal stromal tumor. Am Surg. 2006;72:1225-1230.  [PubMed]  [DOI]  [Cited in This Article: ]
32.  Marks V, Teale JD. Drug-induced hypoglycemia. Endocrinol Metab Clin North Am. 1999;28:555-577.  [PubMed]  [DOI]  [Cited in This Article: ]
33.  Geoghegan JG, Jackson JE, Lewis MP, Owen ER, Bloom SR, Lynn JA, Williamson RC. Localization and surgical management of insulinoma. Br J Surg. 1994;81:1025-1028.  [PubMed]  [DOI]  [Cited in This Article: ]
34.  Gunther RW, Klose KJ, Ruckert K, Beyer J, Kuhn FP, Klotter HJ. Localization of small islet-cell tumors. Preoperative and intraoperative ultrasound, computed tomography, arteriography, digital subtraction angiography, and pancreatic venous sampling. Gastrointest Radiol. 1985;10:145-152.  [PubMed]  [DOI]  [Cited in This Article: ]
35.  Doppman JL, Chang R, Fraker DL, Norton JA, Alexander HR, Miller DL, Collier E, Skarulis MC, Gorden P. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med. 1995;123:269-273.  [PubMed]  [DOI]  [Cited in This Article: ]
36.  Galiber AK, Reading CC, Charboneau JW, Sheedy PF 2nd, James EM, Gorman B, Grant CS, van Heerden JA, Telander RL. Localization of pancreatic insulinoma: comparison of pre- and intraoperative US with CT and angiography. Radiology. 1988;166:405-408.  [PubMed]  [DOI]  [Cited in This Article: ]
37.  Lo CY, Lam KY, Kung AW, Lam KS, Tung PH, Fan ST. Pancreatic insulinomas. A 15-year experience. Arch Surg. 1997;132:926-930.  [PubMed]  [DOI]  [Cited in This Article: ]
38.  Ravi K, Britton BJ. Surgical approach to insulinomas: are pre-operative localisation tests necessary? Ann R Coll Surg Engl. 2007;89:212-217.  [PubMed]  [DOI]  [Cited in This Article: ]
39.  Mabrut JY, Lifante JC, Cherki S, Sin S, Berger N, Peix JL. Is preoperative localization of insulinomas necessary? Ann Chir. 2001;126:850-856.  [PubMed]  [DOI]  [Cited in This Article: ]
40.  Aoki T, Sakon M, Ohzato H, Kishimoto S, Oshima S, Yamada T, Higaki N, Nakamori S, Gotoh M, Ishikawa O. Evaluation of preoperative and intraoperative arterial stimulation and venous sampling for diagnosis and surgical resection of insulinoma. Surgery. 1999;126:968-973.  [PubMed]  [DOI]  [Cited in This Article: ]
41.  Doppman JL, Miller DL, Chang R, Shawker TH, Gorden P, Norton JA. Insulinomas: localization with selective intraarterial injection of calcium. Radiology. 1991;178:237-241.  [PubMed]  [DOI]  [Cited in This Article: ]
42.  Norton JA, Sigel B, Baker AR, Ettinghausen SE, Shawker TH, Krudy AG, Doppman JL, Taylor SI, Gordon P. Localization of an occult insulinoma by intraoperative ultrasonography. Surgery. 1985;97:381-384.  [PubMed]  [DOI]  [Cited in This Article: ]
43.  Norton JA. Intraoperative methods to stage and localize pancreatic and duodenal tumors. Ann Oncol. 1999;10 Suppl 4:182-184.  [PubMed]  [DOI]  [Cited in This Article: ]
44.  Gorman B, Charboneau JW, James EM, Reading CC, Galiber AK, Grant CS, van Heerden JA, Telander RL, Service FJ. Benign pancreatic insulinoma: preoperative and intraoperative sonographic localization. AJR Am J Roentgenol. 1986;147:929-934.  [PubMed]  [DOI]  [Cited in This Article: ]
45.  Wong M, Isa SH, Zahiah M, Azmi KN. Intraoperative ultrasound with palpation is still superior to intra-arterial calcium stimulation test in localising insulinoma. World J Surg. 2007;31:586-592.  [PubMed]  [DOI]  [Cited in This Article: ]
46.  Kalafat H, Mihmanli I, Saribeyoglu K, Belli A. Intraoperative doppler ultrasound: a reliable diagnostic method in insulinoma. Hepatogastroenterology. 2007;54:1256-1258.  [PubMed]  [DOI]  [Cited in This Article: ]
47.  London NJ, Bolia A, Millac P, James RF, Bell PR. Localization of an occult impalpable insulinoma by intraoperative ultrasonography. J R Soc Med. 1988;81:663-664.  [PubMed]  [DOI]  [Cited in This Article: ]
48.  Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA. Intraoperative ultrasound and preoperative localization detects all occult insulinomas; discussion 1025-1026. Arch Surg. 2001;136:1020-1025.  [PubMed]  [DOI]  [Cited in This Article: ]
49.  Lo CY, Lo CM, Fan ST. Role of laparoscopic ultrasonography in intraoperative localization of pancreatic insulinoma. Surg Endosc. 2000;14:1131-1135.  [PubMed]  [DOI]  [Cited in This Article: ]
50.  Spitz JD, Lilly MC, Tetik C, Arregui ME. Ultrasound-guided laparoscopic resection of pancreatic islet cell tumors. Surg Laparosc Endosc Percutan Tech. 2000;10:168-173.  [PubMed]  [DOI]  [Cited in This Article: ]
51.  Jaroszewski DE, Schlinkert RT, Thompson GB, Schlinkert DK. Laparoscopic localization and resection of insulinomas. Arch Surg. 2004;139:270-274.  [PubMed]  [DOI]  [Cited in This Article: ]
52.  Pietrabissa A, Shimi SM, Vander Velpen G, Cuschieri A. Localization of insulinoma by laparoscopic infragastric inspection of the pancreas and contact ultrasonography. Surg Oncol. 1993;2:83-86.  [PubMed]  [DOI]  [Cited in This Article: ]
53.  Fidler JL, Fletcher JG, Reading CC, Andrews JC, Thompson GB, Grant CS, Service FJ. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR Am J Roentgenol. 2003;181:775-780.  [PubMed]  [DOI]  [Cited in This Article: ]
54.  McAuley G, Delaney H, Colville J, Lyburn I, Worsley D, Govender P, Torreggiani WC. Multimodality preoperative imaging of pancreatic insulinomas. Clin Radiol. 2005;60:1039-1050.  [PubMed]  [DOI]  [Cited in This Article: ]
55.  King AD, Ko GT, Yeung VT, Chow CC, Griffith J, Cockram CS. Dual phase spiral CT in the detection of small insulinomas of the pancreas. Br J Radiol. 1998;71:20-23.  [PubMed]  [DOI]  [Cited in This Article: ]
56.  Noone TC, Hosey J, Firat Z, Semelka RC. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab. 2005;19:195-211.  [PubMed]  [DOI]  [Cited in This Article: ]
57.  Semelka RC, Kelekis NL, Molina PL, Sharp TJ, Calvo B. Pancreatic masses with inconclusive findings on spiral CT: is there a role for MRI? J Magn Reson Imaging. 1996;6:585-588.  [PubMed]  [DOI]  [Cited in This Article: ]
58.  Catalano C, Pavone P, Laghi A, Panebianco V, Fraioli F, Pediconi F, Napoli A, Passariello R. Localization of pancreatic insulinomas with MR imaging at 0.5 T. Acta Radiol. 1999;40:644-648.  [PubMed]  [DOI]  [Cited in This Article: ]
59.  Owen NJ, Sohaib SA, Peppercorn PD, Monson JP, Grossman AB, Besser GM, Reznek RH. MRI of pancreatic neuroendocrine tumours. Br J Radiol. 2001;74:968-973.  [PubMed]  [DOI]  [Cited in This Article: ]
60.  Das CJ, Debnath J, Gupta AK, Das AK. MR imaging appearance of insulinoma in an infant. Pediatr Radiol. 2007;37:581-583.  [PubMed]  [DOI]  [Cited in This Article: ]
61.  Hamoud AK, Khan MF, Aboalmaali N, Usadel KH, Wullstein C, Vogl TJ. Mangan-enhanced MR imaging for the detection and localisation of small pancreatic insulinoma. Eur Radiol. 2004;14:923-925.  [PubMed]  [DOI]  [Cited in This Article: ]
62.  Thompson NW, Czako PF, Fritts LL, Bude R, Bansal R, Nostrant TT, Scheiman JM. Role of endoscopic ultrasonography in the localization of insulinomas and gastrinomas. Surgery. 1994;116:1131-1138.  [PubMed]  [DOI]  [Cited in This Article: ]
63.  McLean AM, Fairclough PD. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:177-193.  [PubMed]  [DOI]  [Cited in This Article: ]
64.  Sotoudehmanesh R, Hedayat A, Shirazian N, Shahraeeni S, Ainechi S, Zeinali F, Kolahdoozan S. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine. 2007;31:238-241.  [PubMed]  [DOI]  [Cited in This Article: ]
65.  Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95:2271-2277.  [PubMed]  [DOI]  [Cited in This Article: ]
66.  Gouya H, Vignaux O, Augui J, Dousset B, Palazzo L, Louvel A, Chaussade S, Legmann P. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol. 2003;181:987-992.  [PubMed]  [DOI]  [Cited in This Article: ]
67.  Kasono K, Hyodo T, Suminaga Y, Sugiura Y, Namai K, Ikoma A, Tamemoto H, Imawari M, Kawakami M, Ishikawa SE. Contrast-enhanced endoscopic ultrasonography improves the preoperative localization of insulinomas. Endocr J. 2002;49:517-522.  [PubMed]  [DOI]  [Cited in This Article: ]
68.  Gress FG, Barawi M, Kim D, Grendell JH. Preoperative localization of a neuroendocrine tumor of the pancreas with EUS-guided fine needle tattooing. Gastrointest Endosc. 2002;55:594-597.  [PubMed]  [DOI]  [Cited in This Article: ]
69.  Gines A, Vazquez-Sequeiros E, Soria MT, Clain JE, Wiersema MJ. Usefulness of EUS-guided fine needle aspiration (EUS-FNA) in the diagnosis of functioning neuroendocrine tumors. Gastrointest Endosc. 2002;56:291-296.  [PubMed]  [DOI]  [Cited in This Article: ]
70.  Chang F, Chandra A, Culora G, Mahadeva U, Meenan J, Herbert A. Cytologic diagnosis of pancreatic endocrine tumors by endoscopic ultrasound-guided fine-needle aspiration: a review. Diagn Cytopathol. 2006;34:649-658.  [PubMed]  [DOI]  [Cited in This Article: ]
71.  Jhala D, Eloubeidi M, Chhieng DC, Frost A, Eltoum IA, Roberson J, Jhala N. Fine needle aspiration biopsy of the islet cell tumor of pancreas: a comparison between computerized axial tomography and endoscopic ultrasound-guided fine needle aspiration biopsy. Ann Diagn Pathol. 2002;6:106-112.  [PubMed]  [DOI]  [Cited in This Article: ]
72.  Fritscher-Ravens A, Izbicki JR, Sriram PV, Krause C, Knoefel WT, Topalidis T, Jaeckle S, Thonke F, Soehendra N. Endosonography-guided, fine-needle aspiration cytology extending the indication for organ-preserving pancreatic surgery. Am J Gastroenterol. 2000;95:2255-2260.  [PubMed]  [DOI]  [Cited in This Article: ]
73.  Kann PH, Wirkus B, Keth A, Goitom K. Pitfalls in endosono-graphic imaging of suspected insulinomas: pancreatic nodules of unknown dignity. Eur J Endocrinol. 2003;148:531-534.  [PubMed]  [DOI]  [Cited in This Article: ]
74.  Kann PH, Ivan D, Pfutzner A, Forst T, Langer P, Schaefer S. Preoperative diagnosis of insulinoma: low body mass index, young age, and female gender are associated with negative imaging by endoscopic ultrasound. Eur J Endocrinol. 2007;157:209-213.  [PubMed]  [DOI]  [Cited in This Article: ]
75.  Menzel J, Domschke W. Intraductal ultrasonography may localize islet cell tumours negative on endoscopic ultrasound. Scand J Gastroenterol. 1998;33:109-112.  [PubMed]  [DOI]  [Cited in This Article: ]
76.  Yamao K, Okubo K, Sawaka A, Hara K, Nakamura T, Suzuki T, Shimizu Y, Ozden I. Endolumenal ultrasonography in the diagnosis of pancreatic diseases. Abdom Imaging. 2003;28:545-555.  [PubMed]  [DOI]  [Cited in This Article: ]
77.  Tseng LM, Chen JY, Won JG, Tseng HS, Yang AH, Wang SE, Lee CH. The role of intra-arterial calcium stimulation test with hepatic venous sampling (IACS) in the management of occult insulinomas. Ann Surg Oncol. 2007;14:2121-2127.  [PubMed]  [DOI]  [Cited in This Article: ]
78.  Brandle M, Pfammatter T, Spinas GA, Lehmann R, Schmid C. Assessment of selective arterial calcium stimulation and hepatic venous sampling to localize insulin-secreting tumours. Clin Endocrinol (Oxf). 2001;55:357-362.  [PubMed]  [DOI]  [Cited in This Article: ]
79.  Tsagarakis S, Kaskarelis J, Malagari C, Platis O, Trivizas P, Vrachliotis G, Thalassinos N. Regionalization of occult pancreatic insulinomas with the arterial stimulation venous sampling (ASVS) technique. Clin Endocrinol (Oxf). 1997;47:753-757.  [PubMed]  [DOI]  [Cited in This Article: ]
80.  Doppman JL, Miller DL, Chang R, Gorden P, Eastman RC, Norton JA. Intraarterial calcium stimulation test for detection of insulinomas. World J Surg. 1993;17:439-443.  [PubMed]  [DOI]  [Cited in This Article: ]
81.  Morita S, Machida H, Kuwatsuru R, Saito N, Suzuki K, Iihara M, Obara T, Mitsuhashi N. Preoperative localization of pancreatic insulinoma by super selective arterial stimulation with venous sampling. Abdom Imaging. 2007;32:126-128.  [PubMed]  [DOI]  [Cited in This Article: ]
82.  Jackson JE. Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:229-239.  [PubMed]  [DOI]  [Cited in This Article: ]
83.  Lo CY, Chan FL, Tam SC, Cheng PW, Fan ST, Lam KS. Value of intra-arterial calcium stimulated venous sampling for regionalization of pancreatic insulinomas. Surgery. 2000;128:903-909.  [PubMed]  [DOI]  [Cited in This Article: ]
84.  Won JG, Tseng HS, Yang AH, Tang KT, Jap TS, Kwok CF, Lee CH, Lin HD. Intra-arterial calcium stimulation test for detection of insulinomas: detection rate, responses of pancreatic peptides, and its relationship to differentiation of tumor cells. Metabolism. 2003;52:1320-1329.  [PubMed]  [DOI]  [Cited in This Article: ]
85.  Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242-244.  [PubMed]  [DOI]  [Cited in This Article: ]
86.  Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:213-227.  [PubMed]  [DOI]  [Cited in This Article: ]
87.  Warner RR, O'dorisio TM. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Semin Nucl Med. 2002;32:79-83.  [PubMed]  [DOI]  [Cited in This Article: ]
88.  van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ. Octreoscan radioreceptor imaging. Endocrine. 2003;20:307-311.  [PubMed]  [DOI]  [Cited in This Article: ]
89.  Krausz Y, Bar-Ziv J, de Jong RB, Ish-Shalom S, Chisin R, Shibley N, Glaser B. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors. Am J Gastroenterol. 1998;93:66-70.  [PubMed]  [DOI]  [Cited in This Article: ]
90.  de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ, Krenning EP. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest. 2005;28:132-136.  [PubMed]  [DOI]  [Cited in This Article: ]
91.  Bernard B, Capello A, van Hagen M, Breeman W, Srinivasan A, Schmidt M, Erion J, van Gameren A, Krenning E, de Jong M. Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy. Cancer Biother Radiopharm. 2004;19:173-180.  [PubMed]  [DOI]  [Cited in This Article: ]
92.  Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-2762.  [PubMed]  [DOI]  [Cited in This Article: ]
93.  Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, Langstrom B, Bergstrom M, Eriksson B. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 2005;90:3392-3400.  [PubMed]  [DOI]  [Cited in This Article: ]
94.  Soga J, Yakuwa Y, Osaka M. Insulinoma/hypoglycemic syndrome: a statistical evaluation of 1085 reported cases of a Japanese series. J Exp Clin Cancer Res. 1998;17:379-388.  [PubMed]  [DOI]  [Cited in This Article: ]
95.  Richards ML, Gauger PG, Thompson NW, Kloos RG, Giordano TJ. Pitfalls in the surgical treatment of insulinoma. Surgery. 2002;132:1040-1049; discussion 1049.  [PubMed]  [DOI]  [Cited in This Article: ]
96.  Finlayson E, Clark OH. Surgical treatment of insulinomas. Surg Clin North Am. 2004;84:775-785.  [PubMed]  [DOI]  [Cited in This Article: ]
97.  Rothmund M, Angelini L, Brunt LM, Farndon JR, Geelhoed G, Grama D, Herfarth C, Kaplan EL, Largiader F, Morino F. Surgery for benign insulinoma: an international review. World J Surg. 1990;14:393-398; discussion 398-399.  [PubMed]  [DOI]  [Cited in This Article: ]
98.  Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J. Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors. J Chir (Paris). 2005;142:132-149.  [PubMed]  [DOI]  [Cited in This Article: ]
99.  Shoup M, Brennan MF, McWhite K, Leung DH, Klimstra D, Conlon KC. The value of splenic preservation with distal pancreatectomy. Arch Surg. 2002;137:164-168.  [PubMed]  [DOI]  [Cited in This Article: ]
100.  Hirshberg B, Libutti SK, Alexander HR, Bartlett DL, Cochran C, Livi A, Chang R, Shawker T, Skarulis MC, Gorden P. Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg. 2002;194:761-764.  [PubMed]  [DOI]  [Cited in This Article: ]
101.  Doherty GM, Doppman JL, Shawker TH, Miller DL, Eastman RC, Gorden P, Norton JA. Results of a prospective strategy to diagnose, localize, and resect insulinomas. Surgery. 1991;110:989-996; discussion 996-997.  [PubMed]  [DOI]  [Cited in This Article: ]
102.  Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54 Suppl 4:iv1-iv16.  [PubMed]  [DOI]  [Cited in This Article: ]
103.  Fjallskog ML, Janson ET. Treatment of endocrine pancreatic tumors. Acta Oncol. 2005;44:329-338.  [PubMed]  [DOI]  [Cited in This Article: ]
104.  Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:87-109.  [PubMed]  [DOI]  [Cited in This Article: ]
105.  Johnson MA, Rajendran S, Balachandar TG, Kannan DG, Jeswanth S, Ravichandran P, Surendran R. Central pancreatectomy for benign pancreatic pathology/trauma: is it a reasonable pancreas-preserving conservative surgical strategy alternative to standard major pancreatic resection? ANZ J Surg. 2006;76:987-995.  [PubMed]  [DOI]  [Cited in This Article: ]
106.  Chung JC, Choi SH, Jo SH, Heo JS, Choi DW, Kim YI. Localization and surgical treatment of the pancreatic insulinomas. ANZ J Surg. 2006;76:1051-1055.  [PubMed]  [DOI]  [Cited in This Article: ]
107.  Casanova D, Polavieja MG, Naranjo A, Pardo F, Rotellar F, Gonzalez F, Luzuriaga C, Regano S, Freijanes J. Surgical treatment of persistent hyperinsulinemic hypoglycemia (PHH) (insulinoma and nesidioblastosis). Langenbecks Arch Surg. 2007;392:663-670.  [PubMed]  [DOI]  [Cited in This Article: ]
108.  Gagner M, Pomp A, Herrera MF. Early experience with laparoscopic resections of islet cell tumors. Surgery. 1996;120:1051-1054.  [PubMed]  [DOI]  [Cited in This Article: ]
109.  Mabrut JY, Fernandez-Cruz L, Azagra JS, Bassi C, Delvaux G, Weerts J, Fabre JM, Boulez J, Baulieux J, Peix JL. Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery. 2005;137:597-605.  [PubMed]  [DOI]  [Cited in This Article: ]
110.  Sa Cunha A, Beau C, Rault A, Catargi B, Collet D, Masson B. Laparoscopic versus open approach for solitary insulinoma. Surg Endosc. 2007;21:103-108.  [PubMed]  [DOI]  [Cited in This Article: ]
111.  Iihara M, Obara T. Minimally invasive endocrine surgery: laparoscopic resection of insulinomas. Biomed Pharmacother. 2002;56 Suppl 1:227s-230s.  [PubMed]  [DOI]  [Cited in This Article: ]
112.  Goletti O, Celona G, Monzani F, Caraccio N, Zocco G, Lippolis PV, Battini A, Seccia M, Cavina E. Laparoscopic treatment of pancreatic insulinoma. Surg Endosc. 2003;17:1499.  [PubMed]  [DOI]  [Cited in This Article: ]
113.  Ayav A, Bresler L, Brunaud L, Boissel P. Laparoscopic approach for solitary insulinoma: a multicentre study. Langenbecks Arch Surg. 2005;390:134-140.  [PubMed]  [DOI]  [Cited in This Article: ]
114.  Toniato A, Meduri F, Foletto M, Avogaro A, Pelizzo M. Laparoscopic treatment of benign insulinomas localized in the body and tail of the pancreas: a single-center experience. World J Surg. 2006;30:1916-1919; discussion 1920-1921.  [PubMed]  [DOI]  [Cited in This Article: ]
115.  Gutelius BJ, Korytkowski MT, Carty SE, Hamad GG. Diagnosis and minimally invasive resection of an insulinoma: report of an unusual case and review of the literature. Am Surg. 2007;73:520-524.  [PubMed]  [DOI]  [Cited in This Article: ]
116.  Bozbora A, Barbaros U, Erbil Y, Ozarmagan S, Mercan S. Is laparoscopic enucleation the gold standard in selected cases with insulinoma? J Laparoendosc Adv Surg Tech A. 2004;14:230-233.  [PubMed]  [DOI]  [Cited in This Article: ]
117.  Takamatsu S, Teramoto K, Inoue H, Goseki N, Takahashi S, Baba H, Iwai T, Arii S. Laparoscopic enucleation of an insulinoma of the pancreas tail. Surg Endosc. 2002;16:217.  [PubMed]  [DOI]  [Cited in This Article: ]
118.  Tagaya N, Ishikawa K, Kubota K. Spleen-preserving laparoscopic distal pancreatectomy with conservation of the splenic artery and vein for a large insulinoma. Surg Endosc. 2002;16:217-218.  [PubMed]  [DOI]  [Cited in This Article: ]
119.  Ammori BJ, El-Dhuwaib Y, Ballester P, Augustine T. Laparoscopic distal pancreatectomy for neuroendocrine tumors of the pancreas. Hepatogastroenterology. 2005;52:620-624.  [PubMed]  [DOI]  [Cited in This Article: ]
120.  Edwin B, Mala T, Mathisen O, Gladhaug I, Buanes T, Lunde OC, Soreide O, Bergan A, Fosse E. Laparoscopic resection of the pancreas: a feasibility study of the short-term outcome. Surg Endosc. 2004;18:407-411.  [PubMed]  [DOI]  [Cited in This Article: ]
121.  Pierce RA, Spitler JA, Hawkins WG, Strasberg SM, Linehan DC, Halpin VJ, Eagon JC, Brunt LM, Frisella MM, Matthews BD. Outcomes analysis of laparoscopic resection of pancreatic neoplasms. Surg Endosc. 2007;21:579-586.  [PubMed]  [DOI]  [Cited in This Article: ]
122.  Kano N, Kusanagi H, Yamada S, Kasama K, Ota A. Laparoscopic pancreatic surgery: its indications and techniques: from the viewpoint of limiting the indications. J Hepatobiliary Pancreat Surg. 2002;9:555-558.  [PubMed]  [DOI]  [Cited in This Article: ]
123.  Fernandez-Cruz L, Saenz A, Astudillo E, Martinez I, Hoyos S, Pantoja JP, Navarro S. Outcome of laparoscopic pancreatic surgery: endocrine and nonendocrine tumors. World J Surg. 2002;26:1057-1065.  [PubMed]  [DOI]  [Cited in This Article: ]
124.  Assalia A, Gagner M. Laparoscopic pancreatic surgery for islet cell tumors of the pancreas. World J Surg. 2004;28:1239-1247.  [PubMed]  [DOI]  [Cited in This Article: ]
125.  Carneiro DM, Levi JU, Irvin GL 3rd. Rapid insulin assay for intraoperative confirmation of complete resection of insulinomas. Surgery. 2002;132:937-942; discussion 942-943.  [PubMed]  [DOI]  [Cited in This Article: ]
126.  Gimm O, Konig E, Thanh PN, Brauckhoff M, Karges W, Dralle H. Intra-operative quick insulin assay to confirm complete resection of insulinomas guided by selective arterial calcium injection (SACI). Langenbecks Arch Surg. 2007;392:679-684.  [PubMed]  [DOI]  [Cited in This Article: ]
127.  Parneix M, Rullier E, Gin H, Roche A. Contribution of the artificial pancreas in the diagnosis and surgical treatment of insulinomas. Ann Chir. 1994;48:421-429.  [PubMed]  [DOI]  [Cited in This Article: ]
128.  Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997;73:640-641.  [PubMed]  [DOI]  [Cited in This Article: ]
129.  Usukura M, Yoneda T, Oda N, Yamamoto Y, Takata H, Hasatani K, Takeda Y. Medical treatment of benign insulinoma using octreotide LAR: a case report. Endocr J. 2007;54:95-101.  [PubMed]  [DOI]  [Cited in This Article: ]